ReadeRx Therapeutics Israeli Company

ReadeRx is developing small molecule inhibitors targeting the RNA binding protein IGF2BP1 as a novel treatment for cancer. IGF2BP1 is an oncofetal RNA binding protein expressed in many types of cancers. it regulates RNA function at many levels, including intracellular RNA localization, RNA stability, and translational control. IGFB2P1 is widely expressed in development but is dramatically reduced in normal mature tissues. In many cancers IFG2BP1 is reactivated, assuming a pivotal role in stabilizing key pro-oncogenic RNAs, thereby promoting pro-oncogenic and pro-tumorigenic processes. Consequently, the inhibition of IGF2BP1 emerges as a highly promising strategy for cancer therapy.